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Abstract In this study we have investigated the effects of
insulin, chemical and hyperthermic stresses upon the activity of
the System A amino acid transporter in L6 rat muscle cells.
Uptake of K-methyl-aminoisobutyric acid (Me-AIB), a non-
metabolisable System A substrate, was increased by between
50% and 80% when muscle cells were exposed to a maximally
effective concentration of insulin (100 nM), sodium arsenite
(ARS, 0.5 mM) or a 42‡C heat shock (HS). The observed
activation in System A in response to all three stimuli was
maximal within 20 min and in the case of insulin and ARS
primarily involved an increase in the Vmax of System A
transport. In contrast, HS induced significant increases in both
Vmax and Km of System A transport suggesting that hyperther-
mic stress may activate System A by a mechanism distinct from
that mediating the effects of insulin and ARS. The hormonal
stimulation of System A was blocked by the phosphoinositide
3-kinase (PI3k) inhibitor, wortmannin, but not by rapamycin or
PD 98059 which respectively inhibit the mTOR and classical
MAP kinase pathways. Exposure of L6 cells to ARS, but not
HS, caused a 4.7-fold stimulation in MAPKAP-K2 activity that
was blocked by SB 203580, a specific inhibitor of the stress
activated protein kinase SAPK2/p38. However, neither SB
203580, rapamycin nor wortmannin were able to suppress the
ARS- or HS-induced stimulation in System A transport. In
summary, our results demonstrate that activity of the System A
transporter can be rapidly upregulated in response to hormonal
and stress stimuli through changes in the transport kinetics of the
System A carrier. Our data show that whilst the hormonal
response is PI3k dependent, the signalling mechanisms which
instigate changes in System A activity in response to chemical or
hyperthermic stress do not appear to involve PI3k or components
of the mTOR, p42/p44 MAP kinase or SAPK2/p38 signalling
pathways.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The System A amino acid transporter is expressed in most
mammalian cells and is primarily responsible for the sodium
dependent uptake of short-chain neutral amino acids such as
alanine and glycine [1,2]. Of the classical amino acid transport
systems that have been described, System A is considered to
be the most highly regulated [2] being subject to both acute
and adaptive manipulation. Adaptive regulation occurs over a
period of hours and is thought to involve increased synthesis
of System A carriers and/or synthesis of associated regulatory
proteins based on the observation that this mode of regulation
is sensitive to inhibitors of both RNA and protein synthesis
[2^4]. System A activity can, for example, be stimulated in
numerous cell types in response to amino acid deprivation
and such up-regulation can be suppressed by cycloheximide
and actinomycin D which, respectively, inhibit protein syn-
thesis and DNA transcription [5,6]. Under such circumstances
the activity of other amino acid transport systems such as
ASC and L remain una¡ected indicating that changes in Sys-
tem A transport do not form part of a generalised cell re-
sponse aimed at increasing amino acid uptake [7].
System A can also be acutely regulated in response to in-
sulin [2,8] and certain growth factors such as insulin-like
growth factor 1 (IGF-1) [9] and epidermal growth factor
(EGF) [10] by a mechanism which does not require on-going
protein synthesis. In skeletal muscle, stimulation of System A
by insulin and IGF-1 is phosphoinositide 3-kinase (PI3k) de-
pendent [11,12] and we have recently found that it can also be
activated in muscle cells expressing a constitutively active
form of protein kinase B (PKB), which lies downstream of
PI3k [13]. Evidence is also available in the literature showing
that the activity of System A can be rapidly modulated in
response to changes in muscle cell volume induced by stress-
ing cells in a hyperosmotic environment [14]. However, it
remains unknown if other stress stimuli can also acutely reg-
ulate System A and, if so, whether PI3k or protein kinases
activated in response stresses such as hyperthermia, osmotic
shock and metabolic poisons (e.g. arsenite) [15^19] play a role
in regulating the activity of this amino acid transporter.
In this study we have compared the e¡ects of exposing L6
muscle cells to insulin, arsenite or heat shock on the activity
of the System A amino acid transporter. We have evaluated
what contribution, if any, PI3k and components of the
mTOR, p42/p44 MAP kinase and SAPK2/p38 signalling path-
ways make towards changes in System A activity in response
to hormonal and stress stimuli.
2. Materials and methods
2.1. Materials
Rat L6 skeletal muscle cells were kindly provided by Dr. Amira
Klip (Hospital for Sick Children, Toronto, Canada). K-Minimal es-
sential medium (K-MEM) culture medium, foetal calf serum and anti-
mycotic/antibiotic solution for tissue culture were obtained from Gib-
co-BRL (Paisley, Renfrewshire, Scotland, UK) and human insulin
from Novo Nordisk (Bagsvaerd, Denmark). Sterile trypsin solution,
wortmannin, cycloheximide and sodium arsenite were from Sigma
(Poole, Dorset, UK). All reagent grade chemicals were purchased
from either Sigma or BDH (Poole, Dorset, UK). All radiochemicals
were purchased from New England Nuclear (Hounslow, UK). SB
203580 and PD 98059 were obtained from Calbiochem-Novabiochem
(Nottingham, UK) and protease cocktail inhibitor tablets were pur-
chased from Boehringer Mannheim (Sussex, UK).
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2.2. Cell culture and incubations
Monolayers of L6 muscle cells were cultured to the stage of myo-
tubes as previously described [20^22] in K-MEM containing 2% foetal
calf serum and 1% antimycotic/antibiotic solution (¢nal concentration
100 U/ml penicillin, 100 Wg/ml streptomycin, 250 ng/ml amphotericin
B) at 37‡C in an atmosphere of 5% CO2/95% air. The cells were
cultured in six-well plates and upon formation of myotubes were
routinely deprived of serum for 5 h prior to analysis using serum-
free K-MEM containing 25 mM glucose. During the ¢nal hour cells
were depleted of amino acids by incubation in HEPES bu¡ered saline
(HBS, 20 mM HEPES-Na (pH 7.4), 140 mM NaCl, 2.5 mM MgSO4,
5 mM KCl, 1 mM CaCl2) containing 25 mM glucose. All subsequent
additions to the cells were at the times and concentrations indicated in
the ¢gure legends.
2.3. Preparation of whole cell lysates and assay for MAPKAP-K2
activity
Monolayers of L6 myotubes were treated as described in the ¢gure
legends. HBS containing the relevant stimuli/inhibitors was rapidly
aspirated and the cells washed twice in HBS, placed on ice and lysed
in 0.2 ml of ice-cold lysis bu¡er (50 mM Tris (pH 7.4), 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 1 mM Na orthovanadate, 10 mM
Na-L-glycerophosphate, 50 mM NaF, 5 mM Na pyrophosphate, 0.27
M sucrose, 0.1% (v/v) L-mercaptoethanol, 2 WM microcystin-LR and
one protease cocktail inhibitor tablet per 50 ml lysis bu¡er). Lysates
were centrifuged for 10 min at 14 000Ug and 50 Wg of the resultant
supernatant incubated with 3 Wg anti-MAPKAP-K2 antibody [23]
bound to 5 Wl (settled volume) of protein G-Sepharose for 90 min
shaking at 4‡C. Immunoprecipitates were washed twice with lysis
bu¡er containing 0.5 M NaCl and then twice with lysis bu¡er alone.
The precipitated kinase was assayed in a 50-Wl volume, containing 50
mM Na L-glycerophosphate (pH 7.4), 0.2 mM EGTA, 2.5 WM PKI (a
peptide inhibitor of cyclic AMP dependent protein kinase), 30 WM of
MAPKAP-K2 substrate peptide KKLNRTLSVA [23], 10 mM Mg
acetate and 0.1 mM [Q-32P]ATP for 10 min at 30‡C. MAPKAP-K2
activity was determined by the rate of peptide phosphorylation. One
unit (U) of activity was that amount of MAPKAP-K2 which cata-
lysed the incorporation of 1 nmol of phosphate into substrate in
1 min.
2.4. System A amino acid uptake
Cells were serum and amino acid deprived as indicated previously
and exposed to the appropriate stimulants or inhibitors at the times
and concentrations indicated in the ¢gure legends. System A transport
was measured by incubating cells in 10 WM [14C]Me-AIB (0.1 WCi/ml)
for 10 min as described previously [4,12]. Non-speci¢c tracer binding
was determined by either quantitating cell associated radioactivity in
the presence of a saturating dose of unlabeled Me-AIB (10 mM) or by
inclusion of [3H]mannitol as an extracellular marker. Uptake was
determined by rapidly aspirating the radioactive incubation medium,
followed by three successive washes with ice-cold isotonic saline solu-
tion (0.9% NaCl, w/v). Cell associated radioactivity was determined
by cell lysis in 0.05 M NaOH followed by liquid scintillation counting.
Total cell protein was determined by the Bradford method [24].
2.5. Statistical analysis
Statistical analysis was carried out using a Student’s t-test. Data
were considered statistically signi¢cant at P values 9 0.05.
3. Results and discussion
3.1. System A is rapidly stimulated by chemical stress and
heat shock
L6 myotubes exposed to the chemical stress agent sodium
arsenite (ARS) displayed a time-dependent activation in Sys-
tem A amino acid transport as judged by the cellular uptake
of Me-AIB, a non-metabolisable substrate of the System A
carrier (Fig. 1). The increase in Me-AIB uptake plateaued
after 30 min and was maximally stimulated (V46%) at a
concentration of 0.5 mM Na-arsenite (the induction in System
A activity being assayed at ARS concentrations between 10
WM and 2 mM, data not shown). Me-AIB uptake was also
acutely upregulated by over 2-fold when muscle cells were
subjected to hyperthermic stress (cells were heat shocked at
42‡C for maximum activation). The increase in amino acid
uptake following heat shock was slightly more rapid than
that seen in response to ARS, being signi¢cantly elevated
within 10 min and achieving peak activation after just 20
min (Fig. 1).
The very acute nature with which both ARS and heat shock
stimulate System A transport is highly reminiscent of that
seen following treatment of muscle cells with either insulin
or IGF-1 which increase System A activity by elevating the
Vmax of this transporter [9]. To determine whether the stress-
induced increase in System A was also attributable to changes
in the kinetic properties of the carrier we assayed Me-AIB
uptake in L6 myotubes at di¡erent extracellular concentra-
tions of the amino acid (5 WM^0.75 mM) following a 30-
min treatment period with either 100 nM insulin, 0.5 mM
ARS or heat shock (42‡C). Table 1 shows that insulin and
ARS signi¢cantly increased the Vmax of Me-AIB uptake by
48% and 56%, respectively. Neither insulin nor ARS caused
any signi¢cant changes in the Km (i.e. the concentration of
Me-AIB that gave half maximal activation of the System A).
In contrast, both the Vmax and Km of the System A trans-
porter were increased upon subjecting cells to heat shock
(Table 1). This latter ¢nding implies that whilst ARS and
heat shock both acutely stimulate Me-AIB uptake, the e¡ect
is likely to be mediated by distinct cellular mechanisms.
Nevertheless, neither stimulus is likely to enhance carrier ac-
tivity through changes in protein synthesis based on the ob-
servation that (i) both ARS and heat shock exert their e¡ects
too rapidly for it to be accounted by increases in protein
synthesis and (ii) pre-treatment of L6 cells with cycloheximide,
a protein synthesis inhibitor, failed to suppress the ARS-in-
duced increase in Me-AIB uptake (Table 2). Thus, the stress-
induced activation of System A observed in this study is
clearly di¡erent from that seen in response to, for example,
hyperosmotic shock or cellular amino acid deprivation. These
forms of cell stress enhance System A activity over a few
hours and rely upon de novo synthesis of new carrier mole-
cules and/or that of ancillary proteins that may participate in
the regulation of System A [5^7].
3.2. Intracellular signalling pathways involved in the hormonal
and stress-induced activation of the System A transporter
in L6 myotubes
We have previously shown that in skeletal muscle insulin
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Table 1
E¡ect of insulin, arsenite and heat shock on Me-AIB transport ki-
netics in L6 muscle cells
Condition Vmax (pmol/min/mg protein) Km (WM)
Control 333 þ 38 130 þ 13
Insulin 493 þ 20* 113 þ 10
ARS 519 þ 27* 141 þ 16
HS 848 þ 48* 235 þ 2*
L6 myotubes were exposed to insulin (100 nM), arsenite (0.5 mM) or
heat shock (42‡C) for 30 min prior to measuring System A transport.
Me-AIB uptake was assayed over six di¡erent extracellular concen-
trations of Me-AIB (between 5 and 750 WM) and data subjected to
Hanes-linear transformation to calculate the Vmax and Km as de-
scribed in [4]. The results represent the mean þ S.E.M. from three
experiments each performed in triplicate. The asterisk indicates a stat-
istically signi¢cant change from the control value using a Student’s
t-test, P9 0.05.
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acutely stimulates both System A and glucose transport in a
phosphoinositide 3-kinase (PI3k) dependent manner [12,25].
However, whilst it is generally accepted that the hormonal
stimulation of glucose transport does not involve the p42/
p44 MAP kinases or p70S6k [26,27], the issue of whether these
protein kinases participate in the hormonal and/or stress-in-
duced activation of the System A transporter in muscle re-
mains presently unknown. To address this we monitored the
e¡ects of wortmannin (a potent inhibitor of PI3k), PD 98059
(an inhibitor of the MAP kinase pathway) and rapamycin (an
inhibitor of the mTOR pathway which also blocks the hor-
monal activation of p70s6k [28]) on basal and insulin-stimu-
lated System A transport. The data shown in Table 2 indicates
that insulin stimulated Me-AIB uptake by V60% and that
this was suppressed in the presence of wortmannin; a ¢nding
that is consistent with previous work from our group suggest-
ing that PI3k is involved in the hormonal activation of System
A [12]. In contrast, the insulin-induced increase in Me-AIB
uptake was not signi¢cantly altered by PD 98059 or rapamy-
cin indicating that although the hormone stimulates both
MAP kinase and p70s6k in L6 myotubes [28] neither is in-
volved in the acute upregulation of System A activity by in-
sulin.
The magnitude with which insulin or ARS activated System
A was near maximal since exposing muscle cells to both stim-
uli simultaneously did not result in any additive increase in
Me-AIB uptake (Table 2). It is plausible that the lack of
additivity signals the involvement of a common mechanism
by which insulin and ARS enhance System A activity. We
have recently shown that, like insulin, ARS also induces a
rapid stimulation in PI3k activity based on the observation
that it increases the cellular content of phosphatidyl inositol-
3,4,5-P3 in a wortmannin-sensitive fashion [25]. This ¢nding
raises the possibility that PI3k may be a common signalling
element in the hormonal and stress-mediated increase in Sys-
tem A activity. To test this possibility we investigated whether
wortmannin could block the stimulation in System A trans-
port elicited by ARS and heat-shock. Fig. 2A shows that the
inhibitor caused a small, but signi¢cant reduction in basal
Me-AIB uptake in L6 myotubes, but was unable to suppress
the stress-induced increase in transport activity seen in re-
sponse to ARS or heat shock. Similarly, the use of rapamycin
(Fig. 2B) excludes any involvement of the mTOR pathway in
the acute stimulation of Me-AIB uptake by ARS and heat
shock.
A number of previous studies have shown that exposing
mammalian cells to ARS or heat shock results in activation
of the SAPK2/p38 pathway [15,16]. MAPKAP-K2 is an in
vivo substrate of the stress activated protein kinase, SAPK2/
p38, whose activity is known to be enhanced by both ARS
and heat shock in a number of cell lines [15,19,29]. In Fig. 3A
we show that ARS stimulates MAPKAP-K2 in L6 cells by
V5-fold, but that the kinase was not activated when cells
were subjected to heat shock suggesting that activation of
SAPK2/p38 in L6 cells is stimulus dependent. The increase
in MAPKAP-K2 activity elicited by ARS was abolished by
pre-treating muscle cells with the SAPK2/p38 inhibitor, SB
203580 [16,30] (Fig. 3A). Therefore, to assess whether
SAPK2/p38 was involved in the stress-induced increase in
System A transport we monitored the e¡ects of SB 203580
on Me-AIB uptake. Fig. 3B shows that the inhibitor had no
detectable e¡ect on System A activity in unstimulated muscle
cells and was, moreover, unable to block the ARS- or heat
shock-induced increase in Me-AIB uptake. Collectively, these
¢ndings concur with previous work from our group showing
that PI3k, p70s6k and SAPK2/p38 are not involved in the
cellular stress response that instigates an increase in muscle
glucose transport [25].
The precise nature of the signalling pathway(s) that enhan-
ces amino acid and glucose uptake following exposure of
muscle cells to stresses such as ARS and heat shock thus
remains currently unknown. However, one potential candi-
date that may participate in the stress response is the serine/
threonine kinase, protein kinase B (PKB, also known as Akt).
PKB has been implicated in the insulin-mediated regulation of
6-phosphofructokinase-2-kinase [31] and glycogen synthase
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Table 2
E¡ects of wortmannin, PD 98059, rapamycin and arsenite on basal and insulin-stimulated Me-AIB uptake in L6 cells
Inhibitor/compound Me-AIB uptake (pmol/min/mg protein)
3Insulin (basal) +Insulin
None 24.4 þ 1.2 39.0 þ 1.2*
Wortmannin 18.8 þ 0.9 20.7 þ 1.0
PD 98059 24.1 þ 2.2 35.1 þ 2.6*
Rapamycin 26.8 þ 1.6 40.5 þ 2.4*
Arsenite 41.7 þ 3.3** 38.4 þ 1.8**
Cycloheximide 22.7 þ 1.3 ^
Cycloheximide/arsenite 39.8 þ 1.2** ^
Me-AIB uptake was assayed in L6 myotubes following treatment with insulin (100 nM, 30 min) and/or wortmannin (100 nM, 45 min), PD 98059
(50 WM, 45 min), rapamycin (100 nM, 45 min), sodium arsenite (0.5 mM, 30 min) and cycloheximide (5 Wg/ml) as described in Section 2. Results
represent the mean þ S.E.M. from three separate experiments each conducted in triplicate. * indicates a signi¢cant change (P6 0.05 by Student’s
t-test) from the respective basal uptake or ** that from the uptake observed in cells not treated with insulin or any inhibitors.
Fig. 1. E¡ects of heat shock and arsenite treatment on System A
amino acid transport. L6 myotubes were exposed to either a 42‡C
hyperthermic shock or 0.5 mM sodium arsenite for times indicated
in the ¢gure prior to measuring System A (Me-AIB) uptake as indi-
cated in Section 2.
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kinase 3 [32,33] and more recently we [13], and others [34^36],
have shown that it may also be an important signalling inter-
mediate in the hormonal activation of glucose and System A
amino acid transport in muscle and fat. The activation of
PKB by insulin in L6 cells takes place in PI3k dependent
fashion consistent with the suggestion that it lies downstream
of PI3k in the insulin signalling cascade [37]. However, it is
noteworthy that PKB can also be activated by heat shock and
by L-adrenergic agonists by a mechanism that does not in-
volve the activation of PI3k [38,39]. It is conceivable, there-
fore, that PKB may represent a point of convergence for the
insulin and stress signalling pathways. Such a scenario may, in
part, help explain why the stimulation in System A activity
was not additive when L6 cells were simultaneously chal-
lenged with insulin and ARS (Table 2). Unfortunately there
are no speci¢c inhibitors of PKB that would allow us to read-
ily test its involvement in the stress-mediated increase in Sys-
tem A transport in skeletal muscle, but one approach that we
are currently pursuing involves the over-expression of a dom-
inant-negative form of PKB in L6 cells. This approach may
not only help further de¢ne the role played by PKB in the
hormonal activation of glucose and amino acid transport, but
may provide important insights as to whether it also partic-
ipates in the cellular stress response.
Does the stress-induced increase in amino acid uptake con-
fer any physiological bene¢t to the cell? Since the ‘free’ intra-
cellular amino acid pool is su⁄ciently large it is generally
accepted that supply of amino acids from the extracellular
pool is not a major determinant of the protein synthetic
rate in skeletal muscle [40]. However, it is noteworthy that
two recent studies have highlighted the importance of extra-
cellular amino acid supply as a nutritional signal that initiates
intracellular signalling events. For example, exposure of CHO
cells, hepatocytes and L6 myotubes to high physiological con-
centrations of amino acids results in the activation of p70s6k, a
key participant in the initiation of protein synthesis [41,42],
and PHAS-I phosphorylation [42]. Since increased synthesis
of stress-related proteins (such as those belonging to the heat
shock and GRP protein family) forms an integral part of
cellular survival response [16,43], it is conceivable that the
stress-mediated increase in amino acid uptake represents a
signal transduction event that may help promote protein syn-
thesis via activation of key regulatory molecules, such as
p70s6k.
In summary, we have shown that System A amino acid
transport is rapidly stimulated by insulin, chemical and hyper-
thermic stress in L6 muscle cells. Whilst the hormonal stim-
ulation of System A was mediated in a PI3k dependent fash-
ion, the MAP kinase, mTOR and SAPK2/p38 signalling
pathways do not appear to be involved in mediating the hor-
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Fig. 3. MAPKAP-K2 activity and System A amino acid transport
in L6 cells: the e¡ects of arsenite, heat shock and the SAPK2/p38
inhibitor, SB 203580. L6 myotubes were exposed to either sodium
arsenite (ARS, 0.5 mM), heat shock (HS, 42‡C) and/or SB 203580
(SB, 10 WM) for 30 min. After this pre-treatment period cells were
either (A) lysed and assayed for MAPKAP-K2 activity or (B) used
for assaying of System A (Me-AIB) uptake. The results represent
the mean þ S.E.M. from three experiments each performed in tripli-
cate. Asterisks indicate a statistically signi¢cant change from the
basal value (obtained from unstimulated cells) by Student’s t-test,
P9 0.05.
Fig. 2. E¡ects of wortmannin and rapamycin on the stress-induced
increase in System A transport activity in L6 cells. Muscle cells
were pre-treated with (A) wortmannin (WM, 100 nM) and (B) rapa-
mycin (RAP, 100 nM) for 45 min. During the last 30 min of this
incubation period cells were either exposed to sodium arsenite
(ARS, 0.5 mM) or subjected to a 42‡C heat shock (HS). At the end
of this pre-incubation period the activity of the System A transport-
er was assayed as described in Section 2. Results represent the
mean þ S.E.M. from three separate experiments each performed in
triplicate. Asterisks indicate a signi¢cant change from the basal val-
ue (obtained from unstimulated cells) by Student’s t-test, P9 0.05.
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monal or stress-induced increases in System A amino acid
transport.
Acknowledgements: We are grateful to Mr. F.B. Caudwell for syn-
thesis of the peptide KKLNRTLSVA and providing PKI and to
Dr. C. MacKintosh for Microcystin LR. This work was supported
by the MRC, BBSRC, British Diabetic Association and Wellcome
Trust.
References
[1] Christensen, H.N. (1990) Physiol. Rev. 70, 43^77.
[2] McGivan, J.D. and Pastor-Anglada, M. (1994) Biochem. J. 299,
321^334.
[3] Klip, A., Logan, W.J. and Gagalang, E. (1982) J. Cell. Physiol.
113, 56^66.
[4] McDowell, H.E., Christie, G.R., Stenhouse, G. and Hundal, H.S.
(1995) Am. J. Physiol. 269, C1287^C1294.
[5] Gazzola, G.C., Dall’Asta, V. and Guidotti, G.G. (1981) J. Biol.
Chem. 256, 3191^3198.
[6] Fong, A.D., Handlogten, M.E. and Kilberg, M.S. (1989) Bio-
chim. Biophys. Acta 1022, 325^332.
[7] Tramacere, M., Petronini, P.G., Severini, A. and Borghetti, A.F.
(1984) Exp. Cell Res. 151, 70^79.
[8] Guma, A., Castello, A., Testar, X., Palacin, M. and Zorzano, A.
(1992) Biochem. J. 281, 407^411.
[9] Hundal, H.S., Bilan, P.J., Tsakridis, T., Marette, A. and Klip, A.
(1994) Biochem. J. 297, 289^295.
[10] Moule, S.K. and McGivan, J.D. (1987) Biochem. J. 247, 233^
235.
[11] McDowell, H.E., Walker, T., Downes, C.P. and Hundal, H.S.
(1994) J. Physiol. 482, 5P.
[12] Tsakiridis, T., McDowell, H.E., Walker, T., Downes, C.P., Hun-
dal, H.S., Vranic, M. and Klip, A. (1995) Endocrinology 136,
4315^4322.
[13] Hajduch, E., Alessi, D.R., Hemmings, B.A. and Hundal, H.S.
(1998) Diabetes 47, 1006^1013.
[14] Low, S.Y., Rennie, M.J. and Taylor, P.M. (1997) FASEB J. 11,
1111^1117.
[15] Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Liama-
zares, A., Zamanillo, D., Hunt, T. and Nebreda, A.R. (1994) Cell
78, 1027^1037.
[16] Cohen, P. (1997) Trends Cell Biol. 7, 353^361.
[17] Kortenjann, M. and Shaw, P.E. (1995) Crit. Rev. Oncogen. 6,
99^115.
[18] Hu, Y.H., Metzler, B. and Xu, Q.B. (1997) J. Biol. Chem. 272,
9113^9119.
[19] Lim, C.P., Jain, N. and Cao, X.M. (1995) Oncogene 6, 99^115.
[20] Koivisto, U., Martinez-Valdez, H., Bilan, P.J., Burdett, E., Ram-
lal, T. and Klip, A. (1991) J. Biol. Chem. 266, 2615^2621.
[21] Mitsumoto, Y. and Klip, A. (1992) J. Biol. Chem. 267, 4947^
4962.
[22] Hundal, H.S., Ramlal, T., Reyes, R., Leiter, L.A. and Klip, A.
(1992) Endocrinology 131, 1165^1173.
[23] Stokoe, D., Caudwell, B., Cohen, P.T.W. and Cohen, P. (1993)
Biochem. J. 296, 843^849.
[24] Bradford, M.M. (1976) Anal. Biochem. 71, 248^254.
[25] McDowell, H.E., Walker, T., Hajduch, E., Christie, G., Batty,
I.H., Downes, C.P. and Hundal, H.S. (1997) Eur. J. Biochem.
247, 306^313.
[26] Hausdor¡, S.F., Fingar, D.C. and Birnbaum, M.J. (1996) Sem.
Cell Dev. Biol. 7, 239^247.
[27] Gnudi, L., Frevert, E.U., Houseknecht, K.L., Erhardt, P. and
Kahn, B.B. (1997) Mol. Endocrinol. 11, 67^76.
[28] Cross, D.A.E., Alessi, D.R., Vandenheede, J.R., McDowell,
H.E., Hundal, H.S. and Cohen, P. (1994) Biochem. J. 303, 21^26.
[29] Macfarlane, W.M., Smith, S.B., James, R.F.L., Clifton, A.D.,
Doza, Y.N., Cohen, P. and Docherty, K. (1997) J. Biol. Chem.
272, 20936^20944.
[30] Eyers, P.A., Craxton, M., Morrice, N., Cohen, P. and Goedert,
M. (1998) Chem. Biol. 5, 321^328.
[31] Deprez, J., Vertommen, D., Alessi, D.R., Hue, L. and Rider,
M.H. (1997) J. Biol. Chem. 272, 17269^17275.
[32] Cross, D.A.E., Alessi, D.R., Cohen, P., Andjelkovic, M. and
Hemmings, B.A. (1995) Nature 378, 785^789.
[33] Shaw, M., Cohen, P. and Alessi, D.R. (1997) FEBS Lett. 416,
307^311.
[34] Kohn, A.D., Summers, S.A., Birnbaum, M.J. and Roth, R.A.
(1996) J. Biol. Chem. 271, 31372^31378.
[35] Tanti, J.F., Grillo, S., Gremeaux, T., Co¡er, P.J., Vanobberghen,
E. and Le Marchand Brustel, Y. (1997) Endocrinology 138,
2005^2010.
[36] Cong, L., Chen, H., Li, Y., Zhou, L., McGibbon, M.A., Taylor,
S.I. and Quon, M.J. (1997) Mol. Endocrinol. 11, 1881^1890.
[37] Alessi, D.R. and Cohen, P. (1998) Curr. Opin. Gen. Dev. 8, 55^
62.
[38] Konishi, H., Matsuzaki, H., Tanaka, M., Takemura, Y., Kuroda,
S., Ono, Y. and Kikkawa, U. (1997) FEBS Lett. 410, 493^498.
[39] Moule, S.K., Welsh, G.I., Edgell, N.J., Foulstone, E.J., Proud,
C.G. and Denton, R.M. (1997) J. Biol. Chem. 272, 7713^7719.
[40] Rennie, M.J., Smith, K. and Watt, P.W. (1994) Am. J. Physiol.
266, E298^E307.
[41] Wang, X.M., Campbell, L.E., Miller, C.M. and Proud, C.G.
(1998) Biochem. J. 334, 261^267.
[42] Patti, M.E., Brambilla, E., Luzi, L., Landaker, E.J. and Kahn,
C.R. (1998) J. Clin. Invest. 101, 1519^1529.
[43] Merrick, B.A., Walker, V.R., He, C.Y., Patterson, R.M. and
Selkirk, J.K. (1997) Cancer Lett. 119, 185^190.
FEBS 21257 14-12-98
H.E. McDowell et al./FEBS Letters 441 (1998) 15^19 19
